GSK under fire for vax delay

GlaxoSmithKline (NYSE: GSK) made a splash when it announced recently that it would supply 30 million doses of vaccine each year to protect children in developing nations. However, the Guardian has revealed that when GSK made the commitment it was already under orders from the World Health Organization to do additional testing on its vaccine, Synflorix. GSK planned to deliver it in vials that contain two doses. A provider uses a needle to draw half the vaccine for one person and then uses another needle to draw the second shot, which GSK felt was the most efficient strategy. But the WHO wants to be sure that approach can work in Africa, where additional training is required. The extra testing is likely to delay GSK's delivery until 2012, potentially at the cost of many lives. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.